IP Library Granted Patent US 8,828,359
Granted Patent B2
US 8,828,359 · App. 13/908,540 · Granted Sep 9, 2014

Particulate materials

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,828,359
App. No.
13/908,540
Granted
Sep 9, 2014
Kind
B2
Abstract

Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogs thereof, or derivatives thereof. In some examples, the alkaloid ergotamine contains dihydroergotamine, such as dihydroergotamine mesylate and the hydrofluorocarbon fluid vehicle contains HFA 134a, HFA 227ea, or mixtures thereof.

Claims (22)

1. Particles of an active substance, wherein the particles are non-micronized, solid, have a mass median aerodynamic diameter of less than 10 μm, and exhibit a flocculation volume of about 85% or greater about 1 minute after mixing the particles with a nonsolvent hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v,

wherein the active substance comprises an ergot alkaloid, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.

2. The particles of claim 1 , wherein the ergot alkaloid comprises dihydroergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.

3. The particles of claim 2 , wherein the ergot alkaloid is dihydroergotamine mesylate.

4. The particles of claim 1 , wherein the hydrofluorocarbon fluid vehicle comprises 1,1,1,2-tetrafluoroethane (HFA 134a), 1,1,1,2,3,3,3-heptafluoropropane (HFA 227ea), or mixtures thereof.

5. The particles of claim 1 , wherein the particles exhibit a flocculation volume of about 85% or greater about 5 minutes after mixing the particles and the hydrofluorocarbon fluid vehicle.

6. The particles of claim 5 , wherein the particles exhibit a flocculation volume of about 85% or greater about 10 minutes after mixing the particles and the hydrofluorocarbon fluid vehicle.

7. The particles of claim 6 , wherein the particles exhibit a flocculation volume of about 100% about 10 minutes after mixing the particles and the hydrofluorocarbon fluid vehicle.

8. The particles of claim 1 , wherein the particles are mixed with the hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 3% w/v.

9. The particles of claim 8 , wherein the particles are mixed with the hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.5% w/v to about 1.5% w/v.

10. The particles of claim 1 , wherein the mass median aerodynamic diameter of the particles is about 5 μm or less.

11. The particles of claim 10 , wherein the mass median aerodynamic diameter of the particles is about 3 μm or less.

12. The particles of claim 1 , wherein the active substance is in a crystalline form.

13. Particles of an active substance, wherein the particles are non-micronized, solid, have a mass median aerodynamic diameter of less than 15 μm, and exhibit a flocculation volume of about 35% or greater about 1 minute after mixing the particles with a nonsolvent hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v,

wherein the active substance comprises an ergot alkaloid, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.

14. The particles of claim 13 , wherein the ergot alkaloid comprises dihydroergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.

15. The composition of claim 14 , wherein the ergot alkaloid is dihydroergotamine mesylate.

16. The particles of claim 13 , wherein the hydrofluorocarbon fluid vehicle comprises 1,1,1,2-tetrafluoroethane (HFA 134a), 1,1,1,2,3,3,3-heptafluoropropane (HFA 227ea), or mixtures thereof.

17. The particles of claim 16 , wherein the mass median diameter of the particles is about 10 μm or less.

18. The particles of claim 17 , wherein the mass median diameter of the particles is about 5 μm or less.

19. The particles of claim 13 , wherein the particles exhibit a flocculation volume of about 85% or greater about 10 minutes after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle.

20. The particles of claim 13 , wherein the particles are mixed with the hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 3% w/v.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 31217, FRAME 0776 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036876/0130 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2014
From: KORDIKOWSKI, ANDREAS; WALKER, STEPHEN ERNEST; YORK, PETER
To: NEKTAR THERAPEUTICS UK, LTD.
Reel/Frame 032358/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2014
From: NEKTAR THERAPEUTICS UK, LTD.
To: NEKTAR THERAPEUTICS
Reel/Frame 032359/0007 →
SECURITY AGREEMENT Recorded Sep 16, 2013
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 031217/0776 →